2021 ADA Highlights: Landmark DAPA-CKD Trial in Kidney Disease: Extending the Benefits of SGLT2 Inhibitors to and Beyond Diabetic Neuropathy

370 views
July 14, 2021
Comments 0
Login to view comments. Click here to Login